1
|
Menon LV, Manoj E. Copper perchlorate catalyzed oxidative cyclisation of a novel bishydrazone ligand, formation of an unusual copper complex and in vitro biological implications. J Inorg Biochem 2024; 255:112538. [PMID: 38547785 DOI: 10.1016/j.jinorgbio.2024.112538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Revised: 03/10/2024] [Accepted: 03/21/2024] [Indexed: 04/16/2024]
Abstract
A novel hexadentate bishydrazone ligand, 1,10-bis(di(2-pyridyl)ketone) adipic acid dihydrazone (H2L1) is synthesized and characterized. With copper perchlorate as a catalytic oxidant, the ligand undergoes oxidative cyclisation and resulted in the formation of an unusual copper complex [Cu(L1a)2Cl]ClO4 (1), where L1a is 3-(2-pyridyl)triazolo[1,5-a]-pyridine. The Cu(II) complex was characterized physicochemically, while the molecular structure was confirmed by single crystal X- ray diffraction. In the complex cation, copper(II) is in a distorted trigonal bipyramidal coordination environment, surrounded by two triazolo nitrogen atoms and two pyridyl nitrogen atoms of L1a and a chloride atom. The relevant non covalent intermolecular interactions of the complex quantified using Hirshfeld surface analysis reveals that the O···H/ H···O (27.2%) contacts has the highest contribution. The solution phase bandgaps of the compounds were calculated using Tauc plot, whereas the solid-state band gaps were calculated by Kubelka-Munk model. DFT studies of the compounds indicate that the theoretical calculations corroborate with the experimental data. DPPH antioxidant activity assay of the synthesized compounds showed that the proligand H2L1 has a lower IC50 value (24.1 μM) than that of complex 1 (29.7 μM). The in vitro antibacterial activity was evaluated against Escherichia coli and Staphylococcus aureus, which revealed that complex 1 have excellent activity against E. coli, much as the standard ciprofloxacin. The cytotoxic efficacy investigation of the compounds against A549 (lung) adenocarcinoma cells suggested that H2L1 has more anticancer activity (IC50 value of 149.08 μM) than that of complex 1(IC50 value of 176.70 μM).
Collapse
Affiliation(s)
- Lakshmi V Menon
- Department of Applied Chemistry, Cochin University of Science and Technology, Kochi, Kerala 682 022, India
| | - E Manoj
- Department of Applied Chemistry, Cochin University of Science and Technology, Kochi, Kerala 682 022, India.
| |
Collapse
|
2
|
Dymińska L, Hanuza J, Janczak J, Ptak M, Lisiecki R. Spectroscopic and optical properties of 1,2,4-triazolo[4,3-a]pyridin-3(2H)-one as a component of herbicides. Spectrochim Acta A Mol Biomol Spectrosc 2023; 303:123141. [PMID: 37481842 DOI: 10.1016/j.saa.2023.123141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 07/03/2023] [Accepted: 07/11/2023] [Indexed: 07/25/2023]
Abstract
The herbicides azafenidin [(2-(2,4-dichloro-5-prop-2-ynoxyphenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-3-one)] and flumetsulam [(N-(2,6-difluorophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide)] were subjected to IR, Raman, UV-Vis and emission studies. As triazolopyridine is the most prominent and active component of these herbicides, this molecule was characterised by XRD studies, FTIR, Raman, UV-Vis and emission spectra. The experimental data were compared to the results of the DFT quantum chemical calculations carried out for its optimised structure, IR intensities and Raman activities, HOMO-LUMO transitions, and energies of the singlet and triplet states. The characteristics for triazolopyridine quantities were used in the analysis of the studied herbicides.
Collapse
Affiliation(s)
- Lucyna Dymińska
- Department of Bioorganic Chemistry, Wroclaw University of Economics and Business, Komandorska 118/120, 53-345 Wrocław, Poland.
| | - Jerzy Hanuza
- Institute of Low Temperature and Structure Research, Polish Academy of Sciences, Okólna 2, 50-422 Wrocław, Poland
| | - Jan Janczak
- Institute of Low Temperature and Structure Research, Polish Academy of Sciences, Okólna 2, 50-422 Wrocław, Poland
| | - Maciej Ptak
- Institute of Low Temperature and Structure Research, Polish Academy of Sciences, Okólna 2, 50-422 Wrocław, Poland
| | - Radosław Lisiecki
- Institute of Low Temperature and Structure Research, Polish Academy of Sciences, Okólna 2, 50-422 Wrocław, Poland
| |
Collapse
|
3
|
Hu CH, Neissel Valente MW, Halpern OS, Jusuf S, Khan JA, Locke GA, Duke GJ, Liu X, Duclos FJ, Wexler RR, Kick EK, Smallheer JM. Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO). Bioorg Med Chem Lett 2021; 42:128010. [PMID: 33811992 DOI: 10.1016/j.bmcl.2021.128010] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 03/22/2021] [Accepted: 03/28/2021] [Indexed: 11/26/2022]
Abstract
Myeloperoxidase (MPO), a critical enzyme in antimicrobial host-defense, has been implicated in chronic inflammatory diseases such as coronary artery disease. The design and evaluation of MPO inhibitors for the treatment of cardiovascular disease are reported herein. Starting with the MPO and triazolopyridine 3 crystal structure, novel inhibitors were designed incorporating a substituted pyrazole, which allowed for substituents to interact with hydrophobic and hydrophilic patches in the active site. SAR exploration of the substituted pyrazoles led to piperidine 17, which inhibited HOCl production from activated neutrophils with an IC50 value of 2.4 μM and had selectivity against thyroid peroxidase (TPO). Optimization of alkylation chemistry on the pyrazole nitrogen facilitated the preparation of many analogs, including macrocycles designed to bridge two hydrophobic regions of the active site. Multiple macrocyclization strategies were pursued to prepare analogs that optimally bound to the active site, leading to potent macrocyclic MPO inhibitors with TPO selectivity, such as compound 30.
Collapse
Affiliation(s)
- Carol H Hu
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States.
| | - Meriah W Neissel Valente
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States.
| | - O Scott Halpern
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States
| | - Sutjano Jusuf
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States
| | - Javed A Khan
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States
| | - Gregory A Locke
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States
| | - Gerald J Duke
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States
| | - Xiaoqin Liu
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States
| | - Franck J Duclos
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States
| | - Ruth R Wexler
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States
| | - Ellen K Kick
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States
| | - Joanne M Smallheer
- Research and Development, Bristol-Myers Squibb Company, P. O. Box 5400, Princeton, NJ 08543, United States
| |
Collapse
|
4
|
Shaw SA, Vokits BP, Dilger AK, Viet A, Clark CG, Abell LM, Locke GA, Duke G, Kopcho LM, Dongre A, Gao J, Krishnakumar A, Jusuf S, Khan J, Spronk SA, Basso MD, Zhao L, Cantor GH, Onorato JM, Wexler RR, Duclos F, Kick EK. Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase. Bioorg Med Chem 2020; 28:115723. [PMID: 33007547 DOI: 10.1016/j.bmc.2020.115723] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 08/17/2020] [Accepted: 08/18/2020] [Indexed: 01/15/2023]
Abstract
Myeloperoxidase (MPO) is a heme peroxidase found in neutrophils, monocytes and macrophages that efficiently catalyzes the oxidation of endogenous chloride into hypochlorous acid for antimicrobial activity. Chronic MPO activation can lead to indiscriminate protein modification causing tissue damage, and has been associated with chronic inflammatory diseases, atherosclerosis, and acute cardiovascular events. Triazolopyrimidine 5 is a reversible MPO inhibitor; however it suffers from poor stability in acid, and is an irreversible inhibitor of the DNA repair protein methyl guanine methyl transferase (MGMT). Structure-based drug design was employed to discover benzyl triazolopyridines with improved MPO potency, as well as acid stability, no reactivity with MGMT, and selectivity against thyroid peroxidase (TPO). Structure-activity relationships, a crystal structure of the MPO-inhibitor complex, and acute in vivo pharmacodynamic data are described herein.
Collapse
Affiliation(s)
- Scott A Shaw
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States.
| | - Benjamin P Vokits
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Andrew K Dilger
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Andrew Viet
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Charles G Clark
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Lynn M Abell
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Gregory A Locke
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Gerald Duke
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Lisa M Kopcho
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Ashok Dongre
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Ji Gao
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Arathi Krishnakumar
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Sutjano Jusuf
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Javed Khan
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Steven A Spronk
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Michael D Basso
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Lei Zhao
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Glenn H Cantor
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Joelle M Onorato
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Ruth R Wexler
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Franck Duclos
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| | - Ellen K Kick
- Bristol Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543-5400, United States
| |
Collapse
|